Table 1.
Clinical variables of 853 patients between EPHA5 mutant and wild-type ones
| Variables | EPHA5 mutation (%) | None (%) | P |
|---|---|---|---|
| Total | 65 (100) | 788 (100) | |
| Age | 0.544 | ||
| < 65 | 38 (58.5) | 430 (54.6) | |
| ≥ 65 | 27 (41.5) | 358 (45.4) | |
| Race | 0.521 | ||
| White | 43 (66.2) | 573 (72.7) | |
| Asian | 15 (23.1) | 149 (18.9) | |
| Others | 7 (10.8) | 66 (8.4) | |
| Sex | 0.121 | ||
| Female | 19 (29.2) | 307 (39.0) | |
| Male | 46 (70.8) | 481 (61.0) | |
| Histology | 0.493 | ||
| Squamous | 17 (26.2) | 238 (30.2) | |
| Non-squamous | 48 (73.8) | 550 (69.8) | |
| ECOG | 0.319 | ||
| 0 | 18 (27.7) | 266 (33.8) | |
| 1 | 47 (72.3) | 522 (66.2) | |
| Previous therapy | 0.346 | ||
| First-line chemotherapy | 51 (78.5) | 576 (73.1) | |
| Second-line chemotherapy | 14 (21.5) | 212 (26.9) | |
| Smoking | 0.227 | ||
| Current | 13 (20.0) | 125 (15.9) | |
| Never | 6 (9.2) | 134 (17.0) | |
| Previous | 46 (70.8) | 529 (67.1) | |
| Metastasis sites | 0.004 | ||
| ≤ 3 | 34 (52.3) | 547 (69.4) | |
| > 3 | 31 (47.7) | 241 (30.6) | |
| Therapy | 0.859 | ||
| Atezolizumab | 32 (49.2) | 397 (50.4) | |
| Docetaxel | 33 (50.8) | 9.6) |
Annotation: ECOG, eastern cooperative oncology group. 0, fully active, able to carry on all pre-disease performance without restriction;1, means restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature